ArticleOncotarget2018

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.

Kaiming Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.